Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Tyrosine Kinase Inhibitor; Drug: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]; Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] Sponsors: University of Colorado, Denver; National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Non-Small Cell Lung Cancer | Reclast | Research | Xgeva | Zometa